Clinical and Immunologic Parameters at EOT and for Patients Whose Treatment Continued Beyond Day 90 and 180
| . | Median (IQR) or No. (%)a . | ||
|---|---|---|---|
| . | EOT (n = 60) . | 90 d (n = 59) . | 180 d (n = 39) . |
| Treatment duration, d | |||
| IA | 238.5 (115–374) | 245.5 (155.5–377.5) | 278 (237–418) |
| Non- IA | 197.5 (120–319) | 215 (134–454) | 315 (198–675) |
| Treatment continuation reasonsb | |||
| Lack of clinical/radiographic response | … | 16 (27.1) | 0 |
| Continued immunosuppressive treatment | … | 33 (55.9) | 24 (61.5) |
| Allogeneic hematopoietic cell transplant | … | 28 (47.4) | 11 (28.2) |
| Disease relapse | … | 2 (3.4) | 2 (5.1) |
| Unknown | … | 6 (10.2) | 5 (12.8) |
| Treatment discontinuation reasons | |||
| Treatment completion | 41 (68.3) | … | … |
| Death/Palliative care | 15 (25) | … | … |
| Unknown | 4 (6.7) | … | … |
| Laboratory testsc | |||
| White blood cell count, × 103/mm3 | 4.6 (3.3–6) | 3.9 (2–5.8) | 4 (3–5.5) |
| Absolute neutrophil count, × 103/mm3 | 2.9 (1.6–4.3) | 2.5 (1–3.9) | 2.5 (1.6–3.4) |
| Absolute lymphocyte count, × 103/mm3 | 0.9 (0.5–1.5) | 0.6 (0.4–0.9) | 0.7 (0.3–1.1) |
| Platelet count, × 103/mm3 | 91.5 (18.5–161.5) | 113 (45–149) | 118 (36–165) |
| CD4 count, cells/µL | 232.5 (113–385) | 23.5 (10–100) | 80 (44–97) |
| Immunoglobulin G, g/L | 6 (5.2–9.3) | 6.6 (4.8–8.9) | 6 (5.5–8.5) |
| Aspartate aminotransferase, IU/L | 27.5 (19–44) | 24.5 (14–39) | 17 (14–30) |
| γ-Glutamyltransferase, IU/L | 113 (48–215) | 102 (66–252) | 67 (50–163) |
| Glomerular filtration rate, mL/min/m2 | 60 (60–90) | 60 (60–94) | 71 (60–95) |
| Immunosuppression | |||
| Corticosteroidsd | 13 (21.6) | 7 (13.3) | 11 (36.7) |
| Other immunosuppressive treatment | 22 (36.7) | 27 (45.8) | 22 (73.3) |
| Computed tomography | |||
| Chest | 40 (66.6) | … | … |
| Sinus | 4 (6.7) | … | … |
| Chart documentation | |||
| Treatment discontinuation | 39 (65) | … | … |
| Discussion between hematology and ID | 25 (41.6) | … | … |
| ID consultation | 20 (33.3) | … | … |
| . | Median (IQR) or No. (%)a . | ||
|---|---|---|---|
| . | EOT (n = 60) . | 90 d (n = 59) . | 180 d (n = 39) . |
| Treatment duration, d | |||
| IA | 238.5 (115–374) | 245.5 (155.5–377.5) | 278 (237–418) |
| Non- IA | 197.5 (120–319) | 215 (134–454) | 315 (198–675) |
| Treatment continuation reasonsb | |||
| Lack of clinical/radiographic response | … | 16 (27.1) | 0 |
| Continued immunosuppressive treatment | … | 33 (55.9) | 24 (61.5) |
| Allogeneic hematopoietic cell transplant | … | 28 (47.4) | 11 (28.2) |
| Disease relapse | … | 2 (3.4) | 2 (5.1) |
| Unknown | … | 6 (10.2) | 5 (12.8) |
| Treatment discontinuation reasons | |||
| Treatment completion | 41 (68.3) | … | … |
| Death/Palliative care | 15 (25) | … | … |
| Unknown | 4 (6.7) | … | … |
| Laboratory testsc | |||
| White blood cell count, × 103/mm3 | 4.6 (3.3–6) | 3.9 (2–5.8) | 4 (3–5.5) |
| Absolute neutrophil count, × 103/mm3 | 2.9 (1.6–4.3) | 2.5 (1–3.9) | 2.5 (1.6–3.4) |
| Absolute lymphocyte count, × 103/mm3 | 0.9 (0.5–1.5) | 0.6 (0.4–0.9) | 0.7 (0.3–1.1) |
| Platelet count, × 103/mm3 | 91.5 (18.5–161.5) | 113 (45–149) | 118 (36–165) |
| CD4 count, cells/µL | 232.5 (113–385) | 23.5 (10–100) | 80 (44–97) |
| Immunoglobulin G, g/L | 6 (5.2–9.3) | 6.6 (4.8–8.9) | 6 (5.5–8.5) |
| Aspartate aminotransferase, IU/L | 27.5 (19–44) | 24.5 (14–39) | 17 (14–30) |
| γ-Glutamyltransferase, IU/L | 113 (48–215) | 102 (66–252) | 67 (50–163) |
| Glomerular filtration rate, mL/min/m2 | 60 (60–90) | 60 (60–94) | 71 (60–95) |
| Immunosuppression | |||
| Corticosteroidsd | 13 (21.6) | 7 (13.3) | 11 (36.7) |
| Other immunosuppressive treatment | 22 (36.7) | 27 (45.8) | 22 (73.3) |
| Computed tomography | |||
| Chest | 40 (66.6) | … | … |
| Sinus | 4 (6.7) | … | … |
| Chart documentation | |||
| Treatment discontinuation | 39 (65) | … | … |
| Discussion between hematology and ID | 25 (41.6) | … | … |
| ID consultation | 20 (33.3) | … | … |
Abbreviations: EOT, end of treatment; IA, invasive aspergillosis; ID, infectious diseases.
aData were not available for all patients at EOT or by day 90 and 180 after treatment initiation.
bTreatment continuation reasons were not mutually exclusive, meaning that treatment could have been continued due to >1 reason per patient. Allogeneic hematopoietic cell transplant and disease relapse were included as part of continued immunosuppressive treatment.
cThe following were the only statistically significant results comparing laboratory variables: EOT vs day 90 for absolute lymphocyte count, P = .008; EOT vs day 180 for absolute lymphocyte count, P = .05; EOT vs day 90 for CD4 count, P = .04; EOT vs day 180 for CD4 count, P = .02. All other comparisons were not statistically significant and are not presented on this table.
dCorticosteroids included administration of daily dose of prednisone >10 mg.
Clinical and Immunologic Parameters at EOT and for Patients Whose Treatment Continued Beyond Day 90 and 180
| . | Median (IQR) or No. (%)a . | ||
|---|---|---|---|
| . | EOT (n = 60) . | 90 d (n = 59) . | 180 d (n = 39) . |
| Treatment duration, d | |||
| IA | 238.5 (115–374) | 245.5 (155.5–377.5) | 278 (237–418) |
| Non- IA | 197.5 (120–319) | 215 (134–454) | 315 (198–675) |
| Treatment continuation reasonsb | |||
| Lack of clinical/radiographic response | … | 16 (27.1) | 0 |
| Continued immunosuppressive treatment | … | 33 (55.9) | 24 (61.5) |
| Allogeneic hematopoietic cell transplant | … | 28 (47.4) | 11 (28.2) |
| Disease relapse | … | 2 (3.4) | 2 (5.1) |
| Unknown | … | 6 (10.2) | 5 (12.8) |
| Treatment discontinuation reasons | |||
| Treatment completion | 41 (68.3) | … | … |
| Death/Palliative care | 15 (25) | … | … |
| Unknown | 4 (6.7) | … | … |
| Laboratory testsc | |||
| White blood cell count, × 103/mm3 | 4.6 (3.3–6) | 3.9 (2–5.8) | 4 (3–5.5) |
| Absolute neutrophil count, × 103/mm3 | 2.9 (1.6–4.3) | 2.5 (1–3.9) | 2.5 (1.6–3.4) |
| Absolute lymphocyte count, × 103/mm3 | 0.9 (0.5–1.5) | 0.6 (0.4–0.9) | 0.7 (0.3–1.1) |
| Platelet count, × 103/mm3 | 91.5 (18.5–161.5) | 113 (45–149) | 118 (36–165) |
| CD4 count, cells/µL | 232.5 (113–385) | 23.5 (10–100) | 80 (44–97) |
| Immunoglobulin G, g/L | 6 (5.2–9.3) | 6.6 (4.8–8.9) | 6 (5.5–8.5) |
| Aspartate aminotransferase, IU/L | 27.5 (19–44) | 24.5 (14–39) | 17 (14–30) |
| γ-Glutamyltransferase, IU/L | 113 (48–215) | 102 (66–252) | 67 (50–163) |
| Glomerular filtration rate, mL/min/m2 | 60 (60–90) | 60 (60–94) | 71 (60–95) |
| Immunosuppression | |||
| Corticosteroidsd | 13 (21.6) | 7 (13.3) | 11 (36.7) |
| Other immunosuppressive treatment | 22 (36.7) | 27 (45.8) | 22 (73.3) |
| Computed tomography | |||
| Chest | 40 (66.6) | … | … |
| Sinus | 4 (6.7) | … | … |
| Chart documentation | |||
| Treatment discontinuation | 39 (65) | … | … |
| Discussion between hematology and ID | 25 (41.6) | … | … |
| ID consultation | 20 (33.3) | … | … |
| . | Median (IQR) or No. (%)a . | ||
|---|---|---|---|
| . | EOT (n = 60) . | 90 d (n = 59) . | 180 d (n = 39) . |
| Treatment duration, d | |||
| IA | 238.5 (115–374) | 245.5 (155.5–377.5) | 278 (237–418) |
| Non- IA | 197.5 (120–319) | 215 (134–454) | 315 (198–675) |
| Treatment continuation reasonsb | |||
| Lack of clinical/radiographic response | … | 16 (27.1) | 0 |
| Continued immunosuppressive treatment | … | 33 (55.9) | 24 (61.5) |
| Allogeneic hematopoietic cell transplant | … | 28 (47.4) | 11 (28.2) |
| Disease relapse | … | 2 (3.4) | 2 (5.1) |
| Unknown | … | 6 (10.2) | 5 (12.8) |
| Treatment discontinuation reasons | |||
| Treatment completion | 41 (68.3) | … | … |
| Death/Palliative care | 15 (25) | … | … |
| Unknown | 4 (6.7) | … | … |
| Laboratory testsc | |||
| White blood cell count, × 103/mm3 | 4.6 (3.3–6) | 3.9 (2–5.8) | 4 (3–5.5) |
| Absolute neutrophil count, × 103/mm3 | 2.9 (1.6–4.3) | 2.5 (1–3.9) | 2.5 (1.6–3.4) |
| Absolute lymphocyte count, × 103/mm3 | 0.9 (0.5–1.5) | 0.6 (0.4–0.9) | 0.7 (0.3–1.1) |
| Platelet count, × 103/mm3 | 91.5 (18.5–161.5) | 113 (45–149) | 118 (36–165) |
| CD4 count, cells/µL | 232.5 (113–385) | 23.5 (10–100) | 80 (44–97) |
| Immunoglobulin G, g/L | 6 (5.2–9.3) | 6.6 (4.8–8.9) | 6 (5.5–8.5) |
| Aspartate aminotransferase, IU/L | 27.5 (19–44) | 24.5 (14–39) | 17 (14–30) |
| γ-Glutamyltransferase, IU/L | 113 (48–215) | 102 (66–252) | 67 (50–163) |
| Glomerular filtration rate, mL/min/m2 | 60 (60–90) | 60 (60–94) | 71 (60–95) |
| Immunosuppression | |||
| Corticosteroidsd | 13 (21.6) | 7 (13.3) | 11 (36.7) |
| Other immunosuppressive treatment | 22 (36.7) | 27 (45.8) | 22 (73.3) |
| Computed tomography | |||
| Chest | 40 (66.6) | … | … |
| Sinus | 4 (6.7) | … | … |
| Chart documentation | |||
| Treatment discontinuation | 39 (65) | … | … |
| Discussion between hematology and ID | 25 (41.6) | … | … |
| ID consultation | 20 (33.3) | … | … |
Abbreviations: EOT, end of treatment; IA, invasive aspergillosis; ID, infectious diseases.
aData were not available for all patients at EOT or by day 90 and 180 after treatment initiation.
bTreatment continuation reasons were not mutually exclusive, meaning that treatment could have been continued due to >1 reason per patient. Allogeneic hematopoietic cell transplant and disease relapse were included as part of continued immunosuppressive treatment.
cThe following were the only statistically significant results comparing laboratory variables: EOT vs day 90 for absolute lymphocyte count, P = .008; EOT vs day 180 for absolute lymphocyte count, P = .05; EOT vs day 90 for CD4 count, P = .04; EOT vs day 180 for CD4 count, P = .02. All other comparisons were not statistically significant and are not presented on this table.
dCorticosteroids included administration of daily dose of prednisone >10 mg.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
